For the roughly 38 million Americans living with diabetes, checking blood sugar usually means one thing: breaking the skin. Finger-stick lancets draw a drop of blood several times a day. Continuous glucose monitors like the Dexcom G7 and Abbott FreeStyle Libre 3 use a hair-thin filament inserted just beneath the surface. Every current method approved by the U.S. Food and Drug Administration requires some form of needle or sensor penetration.
A small British-American company called Nemaura Medical wants to change that. Its sugarBEAT system is a disposable adhesive patch, roughly the size of a large coin, that sits on the skin and pulls glucose molecules to the surface using a mild electrical current. No lancet, no filament, no implant. The patch feeds data to a paired app, delivering a new reading every five minutes for up to 24 hours before it is peeled off and replaced. As of June 2026, sugarBEAT holds a CE mark for sale in European markets, and Nemaura has publicly stated its intention to seek U.S. clearance and broader retail distribution. But between a working prototype and a box on a pharmacy shelf, there is a long, obstacle-filled road.
How sugarBEAT actually works
The technical backbone of the device is described in a prospectus supplement Nemaura filed with the U.S. Securities and Exchange Commission. A low-level electric field applied across the patch draws interstitial glucose through the outer layers of skin into a small collection chamber. Inside that chamber, an electrochemical sensor measures glucose concentration and transmits the result wirelessly. Because the electrical current is gentle and the skin is not punctured, the company classifies the approach as “non-invasive,” distinguishing it from both finger sticks and subcutaneous CGMs.
Nemaura’s 2019 annual report confirmed that sugarBEAT had earned its CE mark, the certification required to market a medical device in the European Economic Area. The same filing disclosed clinical data collected across hundreds of patient-days and outlined partnerships intended to support manufacturing and distribution. Importantly, the report framed nearly every sales projection and geographic expansion target as a forward-looking statement, a legal signal that those plans were aspirational, not accomplished.
The accuracy question no one has fully answered
Accuracy is the make-or-break metric for any glucose monitor. Established CGMs are judged by a statistic called mean absolute relative difference, or MARD, which measures how closely a sensor’s readings match a laboratory reference. The Dexcom G7, for example, reports a MARD of about 8.2%, and the Abbott FreeStyle Libre 3 comes in around 7.9%, according to their respective FDA clearance summaries. Lower numbers mean tighter agreement with actual blood glucose.
Nemaura’s SEC filings reference internal accuracy studies but do not publish a comparable MARD figure in the public record. Without that number, clinicians and regulators cannot directly compare sugarBEAT’s performance to devices already on the market. And the stakes are high: an inaccurate reading could lead a patient to take too much or too little insulin, with potentially dangerous consequences.
There is also no publicly available record of FDA clearance for sugarBEAT through either the premarket approval (PMA) pathway or the faster 510(k) route, as of June 2026. Until the FDA issues a decision, the device cannot be legally sold in the United States, and any American launch timeline remains speculative.
The competitive landscape is heating up
Nemaura is not the only company chasing needle-free glucose monitoring. Know Labs, based in Seattle, is developing a platform called Bio-RFID that skips patches entirely. Instead of extracting molecules, it beams radio-frequency signals through the skin and uses machine-learning algorithms to infer glucose levels from how those signals change.
A technical preprint posted on the medRxiv server describes a 28-participant study conducted under controlled lab conditions. The results suggested that RF signals carry usable information about glucose concentration, but the study’s small size, single-site design, and controlled setting prevent any conclusions about real-world reliability. The manuscript has not undergone formal peer review, and no large-scale ambulatory trial data have been publicly reported.
Other players, including startups exploring optical spectroscopy and photoacoustic sensing, are at even earlier stages. The common thread is that none of these non-invasive approaches has yet cleared the FDA’s bar for safety and effectiveness, a bar deliberately set high because glucose data directly influence medication dosing decisions.
Why the FDA bar is so high
Consider what it took for Senseonics to bring its Eversense CGM to market. Eversense uses a tiny sensor implanted under the skin during a brief outpatient procedure, paired with a removable transmitter worn on the surface. The FDA granted it premarket approval only after multi-center clinical trials enrolling hundreds of patients and generating tens of thousands of paired glucose readings across hypoglycemia, normal range, and hyperglycemia, as well as during exercise, meals, and sleep.
Non-invasive devices will almost certainly face similar scrutiny, and possibly more. Their sensing mechanisms are novel, their signal-to-noise challenges are greater, and the consequences of a false reading are identical to those of any other monitor. Yet as of mid-2026, the FDA has not published specific guidance spelling out trial design or performance thresholds for a purely skin-surface glucose device. That means each developer must negotiate expectations with the agency on a case-by-case basis, a process that adds time and uncertainty.
What patients and consumers should watch for
For anyone managing diabetes today, the practical picture is clear. Finger-stick meters and FDA-cleared CGMs remain the only tools backed by robust evidence of accuracy across the full range of real-world conditions. SugarBEAT’s CE mark shows that European regulators judged it to meet baseline safety and performance requirements for that market, but a CE mark does not automatically translate into U.S. approval, insurance coverage, or widespread clinical adoption, especially after the European Union tightened its device regulations under the Medical Device Regulation (MDR) that took full effect in May 2021.
Cost is another open question. Current CGMs can run anywhere from roughly $75 to $400 per month depending on the system and insurance coverage. Nemaura has not disclosed a retail price for sugarBEAT, and without FDA clearance, there is no pathway to U.S. insurance reimbursement.
None of this means the technology is a dead end. Transdermal extraction, radio-frequency sensing, and optical methods are all grounded in real physics, and sensor miniaturization and algorithm refinement continue to advance. Each generation of prototype gets a little closer to the accuracy thresholds that regulators demand. But “closer” is not “there,” and the history of non-invasive glucose monitoring is littered with announcements that never became products.
Patients considering new monitoring options should talk with their endocrinologist or primary care provider and ask a simple question: Does this device have FDA clearance? If the answer is no, it belongs in the “promising but unproven” category, no matter how compelling the marketing materials look. For investors and health-tech watchers, the same principle applies: prioritize primary regulatory and financial documents over press releases, and treat any commercial timeline that lacks a confirmed FDA submission date as provisional.
The day a truly needle-free glucose patch sits on a pharmacy shelf will be a landmark moment for the 537 million adults worldwide living with diabetes. SugarBEAT and its competitors are working toward that moment. They just are not there yet.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
